Calder Biosciences develops conformationally stabilized prefusion subunit vaccines using its proprietary 3D-Vaxlock™ technology, which creates site-specific, covalent crosslinks in proteins to maintain their most effective 3D structure. This approach aims to provide safe and durable protection against viral infections, including RSV and all strains of influenza, addressing the need for effective vaccines in global health.
Funding
Funding not disclosed
Founders
Product
Problem
Current vaccines against viral infections like RSV and influenza often fail to elicit durable, broadly protective immune responses due to the instability of key viral proteins and their tendency to adopt suboptimal conformations. This limits the effectiveness of these vaccines, particularly against emerging viral strains and in vulnerable populations.
Solution
Calder Biosciences is developing a new generation of subunit vaccines that employ its proprietary 3D-Vaxlock™ technology to conformationally stabilize prefusion viral proteins. By engineering site-specific, covalent crosslinks within these proteins, 3D-Vaxlock™ locks them into their most immunogenic 3D structure, eliciting more potent and durable antibody responses. This approach aims to improve vaccine efficacy against a range of viral pathogens, including RSV, all strains of seasonal and pandemic influenza, and Epstein-Barr Virus (EBV). The resulting vaccines are designed to be safe, effective, and tolerable, addressing significant global health needs.
Target Audience
The primary target audience includes individuals at risk of viral infections, such as infants, the elderly, and those with compromised immune systems, as well as global health organizations seeking effective vaccines for widespread use.
Features
- 3D-Vaxlock™ technology: Site-specific covalent crosslinking to stabilize protein immunogens in their optimal 3D conformation.
- Prefusion stabilization: Locks viral proteins into their prefusion state, eliciting more potent neutralizing antibody responses.
- Broadened protection: Designed to protect against multiple strains of a given virus, such as all strains of seasonal and pandemic influenza.
- Subunit vaccine approach: Utilizes only specific viral proteins, enhancing safety and tolerability.
- Vaccine programs targeting RSV, universal influenza, and EBV.